Question explored with the scientific record
Tramadol protractive withdrawals they never tell you about
The short version: tramadol withdrawal is not just opioid withdrawal, and it can be prolonged and atypical, driven by its dual action on serotonin and norepinephrine.
The evidence shows that tramadol withdrawal is more than just opioid-like. A large surveillance study found that while 87% of cases were typical opioid withdrawal, about 1 in 8 was atypical [2]. These atypical cases were more likely to occur at higher doses, but 92% of all withdrawal cases happened at or below the standard 400 mg daily limit [2]. This means dependence can develop at normal therapeutic doses, not just in abuse.
The atypical symptoms likely come from tramadol's serotonin and norepinephrine reuptake inhibition, similar to an antidepressant. A 2015 case report describes a woman with bipolar disorder who developed psychosis (persecutory delusions) after a month on tramadol, which resolved only after the drug was stopped [1]. This is a documented, though rare, withdrawal or side-effect phenomenon. Another case report shows a patient with restless legs syndrome who developed worsening symptoms (augmentation) during long-term tramadol use, which improved significantly after withdrawal [3].
A 2022 pharmacovigilance analysis of two large international databases (FAERS and EudraVigilance) found that dependence and withdrawal signals were strongest for tramadol and oxycodone, with tramadol showing a strong signal for dependence in the European database [4]. This confirms the problem is widespread and recognized in official reporting systems.
The protractive nature is hinted at by the drug's long half-life and active metabolite, and by the fact that withdrawal can include both opioid and serotonergic components. The evidence does not give a specific timeline for "protracted" withdrawal, but the dual mechanism means symptoms like anxiety, depression, insomnia, and sensory disturbances can linger longer than with a pure opioid.
| Withdrawal Type | Proportion of Cases | Key Features |
|---|---|---|
| Typical opioid withdrawal | 87% [2] | Standard opioid symptoms (cramps, sweating, agitation) |
| Atypical withdrawal | ~12.5% (1 in 8) [2] | Serotonin-like symptoms, sensory disturbances, possible psychosis |
My call: tramadol withdrawal is genuinely more complex and can be longer than standard opioid withdrawal due to its SNRI-like activity. The evidence confirms atypical symptoms occur, and dependence can happen at prescribed doses. Confidence: moderate (the evidence is from surveillance and case reports, not controlled trials, but the pattern is consistent and mechanistically plausible).
Sources used 4
-
Tramadol-related psychosis in a patient with bipolar I disorder
This case report describes tramadol HCl/acetaminophen–related psychosis in a 59-year-old woman with bipolar I disorder, detailing the onset during tramadol use, treatment with antipsychotics and lithium, and remission after tramadol withdrawal with implications for pain manageme…
DOI: 10.1017/neu.2014.45 -
Physical dependence on Ultram® (tramadol hydrochloride): both opioid-like and atypical withdrawal symptoms occur
Proactive surveillance found Ultram withdrawal in at least 546 cases; most were typical opioid-like, some atypical, usually at ≤400 mg/day; withdrawal alone should not be equated with abuse.
DOI: 10.1016/s0376-8716(02)00321-6 -
Augmentation of restless legs syndrome with long‐term tramadol treatment
A patient with restless legs syndrome developed augmentation during long-term tramadol treatment, and diurnal and nocturnal symptoms improved after tramadol was withdrawn.
DOI: 10.1002/mds.21342 -
Pharmacovigilance Signals of the Opioid Epidemic over 10 Years: Data Mining Methods in the Analysis of Pharmacovigilance Datasets Collecting Adverse Drug Reactions (ADRs) Reported to EudraVigilance (EV) and the FDA Adverse Event Reporting System (FAERS)
In two pharmacovigilance databases, opioid abuse signals were strongest for fentanyl and oxycodone, while dependence and withdrawal signals were strongest for tramadol and oxycodone, with reports increasing from 2003 to 2018.
DOI: 10.3390/ph15060675